共 34 条
- [31] A phase II, open-label, single-arm, multicenter, efficacy and safety study of 80 mg osimertinib in patients with leptomeningeal metastases (LM) associated with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC): BLOSSOM. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
- [32] ERLOTINIB AS NEOADJUVANT TREATMENT IN ENDOBRONCHIAL ULTRASOUND CONFIRMED STAGE IIIA-N2 NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION (EXON 19 OR 21) (NCT01217619, ESTERN): A PROSPECTIVE, SINGLE ARM, PHASE II CLINICAL TRIAL ANNALS OF ONCOLOGY, 2015, 26
- [33] Correlation between erlotinib-induced rash and efficacy in first-line therapy of patients with advanced non-small cell lung cancer (NSCLC) expressing epidermal growth factor receptor (EGFR)-mutation: A prospective, multi-center, open-label, single-arm, phase II study JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S90 - S91
- [34] A single-arm, phase II study of amivantamab (AMI), lazertinib (L) and pemetrexed (P) for first-line treatment of recurrent/metastatic non-small cell lung cancers (NSCLCS) with epidermal growth factor receptor mutations in Exons 19 or 21 (EGFR 19/21): AMIGO 1 (LACOG0821) ANNALS OF ONCOLOGY, 2023, 34